de Soins Intensifs on Muck Rack

de Soins Intensifs

As seen in: The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with de Soins

Contact de Soins, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pre-emptive TIPS for gastric variceal bleeding in patients with cirrhosis (GAVAPROSEC): an open-label randomised clinical trial

|
By de Soins Intensifs, CHU Besançon, Université Marie, Louis Pasteur
| The Lancet Verified
aService d'Hépatologie et de Soins Intensifs, CHU Besançon, Besançon, France bUniversité Marie et Louis Pasteur, CHU Besançon, EFS, INSERM, RIGHT (UMR 1098), Besançon, France cService d'Hépato-Gastroentérologie et Oncologie Digestive, Centre Hospitalier Universitaire d'Angers, Angers, France dService d'Hépato-Gastroentérologie, Avenue de la République, Chambray-lès-tours, France eUnité de Soins Intensifs d'Hépatologie, Service d'Hépato-Gastroentérologie, Sorbonne Université, Assistance...
Open in Who Shared Issue with article?

Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial

|
By Francis Couturaud, Université Jean Monnet, de Soins Intensifs
| The Lancet Verified
Introduction Venous thromboembolism is a common, potentially fatal disease.1–5 Once venous thromboembolism has been diagnosed, anticoagulation should be taken for at least 3 months to reduce the risk of fatal and non-fatal recurrences.4,5 Extending anticoagulation up to 12 or 24 months reduces the risk of recurrence by at least 80% in patients at high risk of recurrence (ie, patients with a first recurrent venous thromboembolism or with persistent risk factors), but this benefit is lost after...
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified